Marketed in 69 countries across Europe, the Americas, Asia-Pacific, and beyond, Keppra is a globally distributed brand of levetiracetam, classified as an anticonvulsant and antiepileptic. Its broad regulatory footprint means that travellers and expatriates managing a seizure disorder are more likely to find this particular brand abroad than would be the case with most narrower-footprint neurology medications.
Levetiracetam is prescribed in the management of epilepsy and seizure disorders, including focal seizures, generalised tonic-clonic seizures, and juvenile myoclonic epilepsy. The structured indication list further down this page reflects the registered uses recognised across the markets where Keppra is sold, and the exact wording of an indication can vary slightly between national regulators.
Because Keppra is registered in such a wide range of jurisdictions — among them Canada, Australia, China, Argentina, and Belgium — international travellers with epilepsy frequently encounter it under the same brand name, although in some markets levetiracetam circulates instead under generic names or alternative brands. Packaging, tablet appearance, and prescription pathways vary considerably from country to country, and a local pharmacist is generally the most efficient way to confirm whether a levetiracetam product on the shelf matches what a patient takes at home.
Other antiepileptic medications also exist worldwide, both within the broader anticonvulsant category and as part of distinct mechanistic families, but they are not freely interchangeable with levetiracetam. Continuity of seizure control is sensitive to changes in molecule, formulation, and timing, so any change of brand, switch to a generic, or substitution for a different antiepileptic should be planned with the prescribing neurologist or general practitioner rather than improvised at a pharmacy counter while travelling.
